Table 1 Breast cancer (Series 1)

From: PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and progression

Variables

PRSS2 epithelium

PRSS2 TME

Low (n = 458) n %

High (n = 60) n %

OR

95% CI

P valuea

Low (n = 428) n %

High (n = 90) n %

OR

95% CI

P valuea

Grade

    

<0.001

    

<0.001

1–2

391 (91.1)

38 (8.9)

1.0

  

369 (86.0)

60 (14.0)

1.0

  

3

67 (75.3)

22 (24.7)

3.4

1.9, 6.1

 

59 (66.3)

30 (33.7)

3.1

1.9, 6.1

 

ER

    

0.003

    

0.001

Pos

396 (90.2)

43 (9.8)

1.0

  

373 (85.0)

66 (15.0)

   

Neg

62 (78.5)

17 (21.5)

2.5

1.4, 4.7

 

55 (69.6)

24 (30.4)

2.5

1.4, 4.3

 

Mitotic ctb

    

<0.001

    

<0.001

Low ≤5.5

349 (91.8)

31 (8.2)

1.0

  

328 (86.3)

52 (13.7)

   

High >5.5

103 (78.6)

28 (21.4)

3.1

1.8, 5.3

 

93 (71.0)

38 (29.0)

2.6

1.6, 4.2

 

Ki67b

    

<0.001

    

<0.001

Low ≤31.5

351 (91.6)

32 (8.4)

1.0

  

333 (86.9)

50 (13.1)

   

High >31.5

101 (78.9)

27 (21.1)

2.9

1.7, 5.1

 

88 (68.8)

40 (31.2)

3.0

1.9, 4.9

 

CK5/6c

    

0.008

    

<0.001

Neg = 0

401 (98.9)

45 (10.1)

1.0

  

378 (84.8)

68 (15.2)

   

Pos >0

52 (78.8)

14 (21.2)

2.4

1.2, 4.7

 

44 (66.7)

22 (33.3)

2.4

1.0, 6.0

 

pMVDd

    

0.013

    

0.004

Low <4.59

112 (90.3)

12 (9.7)

1.0

  

109 (87.9)

15 (12.1)

   

High ≥4.59

34 (75.6)

11 (24.4)

3.02

1.2, 7.5

 

31 (68.9)

14 (31.1)

3.3

1.4, 7.5

 

GMPd

    

0.006

    

0.005

Absent

116 (89.9)

13 (10.1)

1.0

  

112 (86.8)

17 (13,2)

   

Present

29 (72.5)

11 (27.5)

3.4

1.4, 8.3

 

27 (67.5)

13 (32.5)

3.2

1.4, 7.3

 
  1. n number of patients, OR odds ratio, CI confidence interval, ER estrogen receptor, CK5/6 cytokeratin 5/6, pMVD proliferative microvessel density, GMP glomeruloid microvascular proliferation.
  2. Series 1 (n = 518).
  3. aPearson’s chi-squared test (two-sided).
  4. bCutoff value by upper quartile. Seven cases lack information on Ki67 and mitotic count (mitoses/mm2).
  5. cSix cases lack information on CK5/6 status.
  6. dThree hundred and forty-nine cases lack information on pMVD (Nestin + /Ki67+ vessels) and GMP status.
Back to article page